Compare International Flavors & Fragrances Inc. Common Stock (IFF) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Flavors & Fragrances Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? International Flavors & Fragrances Inc. Common Stock trades at $89.51 (market cap $22.50B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.5× International Flavors & Fragrances Inc. Common Stock's market cap, and International Flavors & Fragrances Inc. Common Stock pays a 1.81% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Flavors & Fragrances Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| IFF | NTRA | |
|---|---|---|
Market Cap | $22.50B | $57.03B |
Volume | 3,000,517 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $89.60 | $425.64 |
52-Week Low | $61.49 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $28.18B | $56.18B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IFF trades at $88.2, up 3.81% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $361 million in 2025 but returned to profitability in 2026 with $277 million net income. Recent news highlights product innovations like AQUASCENT™ and life-stage dairy insights. Analyst consensus is strongly bullish with a $95 price target, though valuation ratios like P/E of 80.92 appear elevated relative to earnings.
The outlook for IFF hinges on sustaining its 2026 profitability turnaround and executing growth initiatives. Investment opportunities include market leadership in flavors and fragrances and new technology launches. Key risks are high debt levels, competitive pressures, and sensitivity to consumer spending trends. The stock's upside is supported by analyst optimism but requires careful monitoring of earnings consistency.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About International Flavors & Fragrances Inc. Common Stock
International Flavors & Fragrances develops ingredients and solutions used in food, beverages, personal care, home care, health, and biosciences applications. Its portfolio includes flavors, fragrances, cultures, enzymes, and nutrition ingredients.
Read more on IFF →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
